SAVA241004C31000
- 0.16
- -0.18-52.94%
Cassava Sciences Newsroom
Why Cassava Sciences Stock Dived by Almost 11% Today
US Equities Markets End Mixed Friday as Fed's Preferred Inflation Metric Meets Expectations
Top Midday Decliners
Stocks Making the Biggest Moves Midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and More
Cassava Sciences Unusual Options Activity
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday
Cassava Sciences Shares Drop in Pre-open Trade After $40 Mln SEC Settlement
12 Health Care Stocks Moving In Friday's Pre-Market Session
Biggest Stock Movers Friday: BB, BMY, and More
These Stocks Are Moving the Most Today: Costco, Bristol Myers, EchoStar, Cassava Sciences, Trump Media, and More -- Barrons.com
Alzheimer's Drug Developer Cassava Paying $40 Million to Settle Doctored Data Claims -- WSJ
Stocks to Watch: Cassava Sciences, Scholastic, MeridianLink
Cassava Sciences Resolves SEC Investigation
SEC Charges Cassava Sciences, Two Former Executives For Misleading Claims About Alzheimer's Clinical Trial; Company To Pay Civil Penalty Of $40M
Express News | U.S. SEC Says It Charges Cassava Sciences, Two Former Executives for Misleading Claims About Alzheimer’s Clinical Trial
Cassava Sciences (SAVA.US) received DSMB approval for the late-stage trial progress of Alzheimer's disease therapy.
Cassava Sciences announced that it has completed the third mid-stage safety review of simufilam in an important late-stage clinical trial for the treatment of Alzheimer's patients currently being conducted by the company.
Cassava Sciences' On-going Late Stage Trials for Alzheimer's Treatment Gets DSMB Nod
Express News | Cassava Sciences Inc - Dsmb Recommends Continuation of Phase 3 Trials Without Modification
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
Express News | Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam on-Going Phase 3 Trials